PT

Dados B3 › Stocks › BIOM3

Healthcare

BIOMM SA

BIOM3 — BIOMM SA

CNPJ 04.752.991/0001-10 · listed classes: BIOM3 · CVM code 19305

Empresa brasileira com sua atividade focada no desenvolvimento e comercialização de medicamentos biotecnológicos por meio de parcerias estratégicas e fabricação própria.As filed by the company in its registration form (FCA), reference 2026-01-01 · CVM sector: Farmacêutico e Higiene

Nível 2 de Governança Corporativalisting segment
2001founded
Nova Lima · MGheadquarters
Privadocontrol
Itaú Corretora de Valores S.A.share registrar
KPMG Auditores Independentes Ltda.auditor
biomm.cominvestor site
R$ 0.3 mavg. daily traded value (63 sessions)

Verdict

Net margin -2.5%; ROIC -1.1%; debt 16.1x EBITDA; P/E does not apply (negative profit); 2025 data, no relevant restatement.

Confidence flag: Clean data

Data for fiscal year 2025, received by the CVM on 2026-04-17; 4 of the 5 core figures published; last restatement recorded in 2020.

Does the company make money?

Is it sound or indebted?

Is the share expensive or cheap relative to the sector and its own history?

Descriptive: number, numeric band and comparison with the sector, the company's own history and the whole universe. Not investment advice. JSON · how the verdict works

Follow BIOM3: get an e-mail when profit turns into loss, debt or margin change band, or the statements are restated. That is all, and you can cancel in one click. See every event already recorded for BIOM3.

Quote

R$ 6.13close of 2026-09-25 · B3 (COTAHIST), updated nightly — the price the API, the MCP and the dump serve

1m -4.8% · 12m -36.6% · YTD -15.1% · 52-week R$ 5.45–10.30

15-minute delayed quote, shown by TradingView — display only: it never enters our API, MCP or dump
Close, weekly, 5 years · return -61.0% (-17.2% a year) · not split-adjustedR$ 6.13 2026-09-25
high 2024-05-03: R$ 18.37low 2023-04-20: R$ 3.652026-09-25: R$ 6.13
2021low R$ 3.65 · high R$ 18.372026

Return by window

1 month3 months1 year2 years5 years10 years
Price-4.8%+0.8%-36.6%-38.9%-58.7%+3.9% 1×
With dividends reinvested-4.8%+0.8%-36.6%-38.9%-58.7%+3.9%
Real, net of inflation (IPCA to 08/2026)-4.8%+1.0%-38.9%-44.0%-67.9%-35.5%
R$ 1,000 would be worthR$ 952R$ 1,008R$ 634R$ 611R$ 413R$ 1,039

Closing prices from the base up to 2026-09-25. The starting price is adjusted by the corporate actions checked against the price (the small mark says how many); a jump they do not explain leaves the window blank. Reinvestment buys more shares at the close of the ex-date, with no tax or cost; only the main ticker class. The real line divides the reinvested return by the IPCA accumulated in the window (Banco Central series 433, monthly, edge months pro rata by days); the latest month is only published around the 10th of the following month.

Corporate actions

last day with rightseventmultipliercheck
2024-02-20stock split inferred1.42× sharesnot checked
2020-03-13stock split inferred1.27× shareschecked against the price move
2013-06-12stock split inferred1.78× sharesnot checked

Why the price chart jumps: prices are not split-adjusted. Inferred means detected from the share count and the price, not announced in the exchange file.

Valuation

Today

R$ 839 mmarket value
close of 2026-09-25 × sharesprice × shares outstanding
R$ 892 menterprise value
+ net debt 2025market value + net debt
R$ -0.05EPS 2025
profit per sharenet income for the year ÷ shares
R$ 2.29BVPS 2025
book value per shareshareholders' equity ÷ shares
94.3P/E 12m
to 2T26today's market value ÷ net income of the last 12 months (built by identity from the quarterly filings)
2.58P/B 2T26
latest quarterly balancetoday's market value ÷ equity to controlling shareholders at quarter end
3.2%ROE 12m
to 2T26net income of the last 12 months ÷ average equity over the same 12 months
2.3%net margin 12m
to 2T26net income ÷ net revenue, both over the last 12 months
136.9 mshares outstandinglatest public count, treasury excluded

Snapshot: today's close over the latest public share count. Cards marked 12m use the last four quarterly filings; the others use the 2025 annual filing. The multiples below are point-in-time: priced on the day the filing became public.

At the filing date (point-in-time)

-146.5P/E 2025
price of 2026-03-25 · sector 15.8 · 6 cos. · 1st of 7price ÷ earnings per share for the year
3.1P/B 2025
price of 2026-03-25 · sector 1.5 · 6 cos. · 5th of 7price ÷ book value per share
310.5EV/EBITDA 2025
price of 2026-03-25 · sector 7.2 · 6 cos. · 7th of 7enterprise value on the filing date ÷ EBITDA for the year (other sites use trailing 12 months and today's price)
-14.1%FCF yield 2025
price of 2026-03-25 · sector 10.8% · 6 cos. · 7th of 7(operating cash flow + capex) ÷ market value
-2.3%ROE 2025
sector 0.8% · 14 cos. · 9th of 15net income to controlling ÷ average equity
-1.1%ROIC 2025
sector 11.9% · 6 cos. · 7th of 7EBIT × (1 − effective tax rate) ÷ average invested capital (gross debt + total equity − cash − investments), goodwill included — /metodologia/roic
P/E, P/B and EV/EBITDA use the price of 2026-03-25 (R$ 7.16), the first one after the 2025 filing became public on 2026-03-25 — point-in-time, not the 31 December price. 1 caveat

By theme, fiscal year 2025

Valuation

P/Receita todaymarket value ÷ net revenue for the year3.12×
EV/Receita todayenterprise value ÷ net revenue3.31×
P/EBITDA todaymarket value ÷ EBITDA252.08×
Earning yield todaynet income ÷ market value (the inverse of P/E)-0.8%

Debt and liquidity

Dívida líquida/PLnet debt ÷ shareholders' equity0.17×
Dívida bruta/PLshort- and long-term borrowings ÷ equity0.31×
Dívida líquida/EBITDAnet debt ÷ EBITDA for the year16.05×
PL/Ativosequity ÷ total assets0.60×
Passivos/Ativos(total assets − equity) ÷ total assets0.40×
Liquidez correntecurrent assets ÷ current liabilities2.23×

Efficiency

Margem brutagross profit ÷ net revenue31.6%
Margem EBITDAEBITDA ÷ net revenue1.2%
Margem EBITEBIT ÷ net revenue-1.9%
Margem líquidanet income ÷ net revenue-2.5%

Profitability

ROEnet income to controlling ÷ average equity-2.3%
ROICEBIT × (1 − effective tax rate) ÷ average invested capital (gross debt + total equity − cash − investments), goodwill included-1.1%
ROAnet income ÷ total assets-1.4%
Giro do ativonet revenue ÷ total assets0.51×

Growth

Receita, 1 anorevenue this year ÷ previous year − 188.4%
Receita, CAGR 5 anoscompound annual growth of revenue over 5 years35.6%

Standardized accounts and published indicators of the fiscal year; items marked today divide today's market value or enterprise value by an account of that year.

Indicators, year by year

Four indicators as charts and the full table below. A hollow point carries a caveat; a gap is a year without the figure — we never draw a line across a hole. In the table, the arrow opens the path from the figure down to the line in the regulator's file; a cell with ! carries a caveat; a dashed dash is a suppressed figure — hover to see why. Nothing is hidden.

Fact checklist 3 of 9

Nine objective checks with the threshold written in each line and the figure behind it. Descriptive, not a recommendation; the thresholds are ours and are declared.

ROE-2.3% 2025
2013: -23.1%2014: -11.8%2015: 7.5%2016: -50.4%2017: -60.9%2018: -51.5%2019: -43.0%2020: -41.0%2021: -53.0%2022: -68.4%2023: -59.1%2024: -40.0%2025: -2.3%
20102025
ROIC-1.1%! 2025
2013: -12.3% — aliq_fallback_342014: -13.6% — aliq_fallback_342015: -2.1% — aliq_travada_452016: -18.9% — aliq_fallback_342017: -14.7% — aliq_fallback_342018: -14.1% — aliq_fallback_342019: -18.5% — aliq_fallback_342020: -16.6% — aliq_fallback_342021: -18.1% — aliq_fallback_342022: -24.4% — aliq_fallback_342023: -21.3% — aliq_fallback_342024: -23.1% — aliq_fallback_342025: -1.1% — aliq_fallback_34
20102025
Net margin-2.5% 2025
2010: -487.2%2017: -37017.5%2018: -2717.9%2019: -624.0%2020: -120.6%2021: -74.9%2022: -88.2%2023: -68.7%2024: -54.0%2025: -2.5%
20102025
Point-in-time P/E-146.5x! 2025
2010: -11.4x — acoes_do_fre_sem_tesouraria;pl_negativo;pl_nao_positivo;sem_ebitda;sem_capex2011: -10.8x — acoes_do_fre_sem_tesouraria;pl_negativo;pl_nao_positivo2012: -9.8x — acoes_do_fre_sem_tesouraria;pl_negativo;pl_nao_positivo2013: -26.4x — acoes_do_fre_sem_tesouraria;pl_negativo2014: -16.3x — acoes_do_fre_sem_tesouraria;acoes_defasadas;pl_negativo2015: 19.5x — acoes_do_fre_sem_tesouraria;acoes_defasadas2016: -5.1x — acoes_do_fre_sem_tesouraria;acoes_defasadas;pl_negativo2017: -5.7x — acoes_do_fre_sem_tesouraria;acoes_defasadas;pl_negativo2018: -5.5x — acoes_do_fre_sem_tesouraria;acoes_defasadas;pl_negativo2019: -11.1x — acoes_do_fre_sem_tesouraria;acoes_ajustadas_por_evento;acoes_defasadas;pl_negativo2020: -15.6x — pl_negativo2021: -10.9x — pl_negativo2022: -4.0x — pl_negativo2024: -12.5x — pl_negativo;preco_2_anos_apos_o_exercicio2025: -146.5x — pl_negativo
20102025

Full table

indicator2010201120122013201420152016201720182019202020212022202320242025sector
ROE ⟶———-23.1%-11.8%7.5%-50.4%-60.9%-51.5%-43.0%-41.0%-53.0%-68.4%-59.1%-40.0%-2.3%0.8%
ROIC ⟶———-12.3%!-13.6%!-2.1%!-18.9%!-14.7%!-14.1%!-18.5%!-16.6%!-18.1%!-24.4%!-21.3%!-23.1%!-1.1%!11.9%
ROA ⟶-87.1%!-53.6%-135.5%-13.7%-8.0%4.0%-19.5%-15.3%-15.0%-16.1%-17.2%-19.9%-23.9%-21.6%-19.1%-1.4%1.6%
Gross margin ⟶50.3%——————35.0%15.6%5.8%23.8%25.2%15.2%19.7%12.5%31.6%30.8%
EBIT margin ⟶-483.7%!——————-34,389.3%!-2,341.9%!-588.2%!-94.7%-61.3%-82.2%-61.4%-56.8%-1.9%12.9%
Net margin ⟶-487.2%——————-37,017.5%-2,717.9%-624.0%-120.6%-74.9%-88.2%-68.7%-54.0%-2.5%2.6%
Revenue growth (1y) ⟶—-100.0%!——————1,420.4%471.1%555.9%82.5%-2.0%12.6%20.9%88.4%4.3%
Revenue growth (5y CAGR) ⟶————————————299.6%137.4%74.1%35.6%13.5%
Net debt/EBITDA ⟶———————————————16.05x1.67x
Current ratio ⟶0.43x0.38x0.08x9.26x16.42x9.41x2.61x1.49x2.66x2.44x3.03x1.80x1.98x1.52x2.72x2.23x1.67x

In reais, year by year

The three statements behind the ratios — income statement, balance sheet and cash flow — in the standardized lines, consolidated as filed (or parent-only when that is what the company files). EBITDA and net debt follow the published methodology; gross debt, cash and investments and free cash flow are sums the line names spell out.

line20102011201220132014201520162017201820192020202120222023202420252T26TTM
Income statement
Net revenue (R$ m)10000000295910710511814326989384
Cost of goods and services (R$ m)-0000000-0-1-8-45-80-89-95-125-184-54-240
Gross profit (R$ m)000000000114271623188536145
EBITDA (R$ m)—-4-12-7-16-3-32-35-35-48-45-54-74-61-693——
Depreciation and amortization (R$ m)—00000002510121211129——
EBIT (operating result) (R$ m)-4-4-12-8-17-3-33-35-37-53-56-66-86-73-81-5946
Pre-tax profit (R$ m)-4-5-14-10-1316-50-41-43-56-71-80-93-81-77-7542
Income taxes (R$ m)00000-743-0-0-0-01-0-10-3-2
Net income (R$ m)-4-5-14-10-138-46-38-43-56-71-80-93-81-77-7240
Net income (controlling) (R$ m)-4-5-14-10-138-46-38-43-56-71-80-93-83-77-729
Balance sheet
Total assets (R$ m)5138138180230237262306389435370405345466524615615
Current assets (R$ m)131951111305164110148201142184128242281367367
Current liabilities (R$ m)391610714204341616679928489126237237
Gross debt (short + long term) (R$ m)061324783117155147156188184172154121979393
Cash and investments (R$ m)03121811153941831051425510554143431010
Net debt (R$ m)-0312-19-34-327911464514612968100-2253——
Shareholders' equity (R$ m)-4-9-221091071156659106154191112159123263314325325
Cash flow
Operating cash flow (R$ m)-5-2-7-11-20-14-38-54-44-81-97-94-63-75-92-112——
Capital expenditures (R$ m)—-1-1-32-24-34-63-6-1-7-5-7-5-6-19-27——
Free cash flow (FCO + capex) (R$ m)—-3-8-42-43-48-101-60-45-88-102-101-68-81-111-139——

The two right-hand columns come from the quarterly filing (ITR): the latest quarter alone and the last 12 months (TTM) built by the same identity as the TTM P/E. EBITDA and net debt have no quarterly series here.

The current year, quarter by quarter

As the company filed it in its interim report. The fourth quarter does not exist on its own in that filing — the closed year comes in the annual one, and we do not derive a Q4, so that a figure we computed never sits beside the figures the company reported. Filed on is the date the report became public, and the price is taken from it.

quarterrevenue (R$ m)profit (R$ m)net marginP/E TTMP/Bfiled on
2024T1!38.6-17.1-44.3%-32.16.202024-05-15
2024T2!32.1-18.3-57.0%-18.73.712024-08-13
2024T3!32.3-16.3-50.5%-20.14.212024-11-13
2025T1!39.6-11.7-29.6%-16.65.102025-05-15
2025T2!27.2-13.7-50.6%-12.53.812025-08-14
2025T3!35.8-10.6-29.6%-14.13.612025-11-14
2026T1!92.519.020.6%-152.53.152026-05-15
2026T289.41.82.1%87.72.402026-08-14

Full series, every quarter: GET /empresas/BIOM3/trimestres

Dividends

No ex-date or payment scheduled in the base (exchange announcements through 2026-09-21 · filings to the regulator through 2026-09-18).

No dividends recorded. Note this can mean two different things — the company pays none, or we could not confirm. sem_proventos

Shareholders and free float

72.38%free float
99,052,303 sharesshares outstanding held by the market, as filed in the FRE
2,594shareholders
2,458 individuals · 136 companies · 0 institutionalcount at the last shareholders meeting, from the FRE
100% ON e PNtag along (minimum)
Nível 2 de Governança Corporativaminimum guaranteed by the listing segment or by law; the bylaws may grant more
shareholdertype% ON% PN% total
Alaska Investimentos LtdaPJ26.15%0.00%26.15%
BTGP GESTÃOPJ12.20%0.00%12.20%
WALFRIDO SILVINO DOS MARES GUIA NETO agreementPF5.53%0.00%5.53%
TMG/IBR L.P. agreementPJ5.44%0.00%5.44%
BNDES Participações - BNDESPAR agreementPJ5.12%0.00%5.12%
ITALO AURELIO GAETANIPF3.16%0.00%3.16%
Samos Participações Ltda.PJ2.71%0.00%2.71%
TMG/IBR L.P.PJ1.81%0.00%1.81%
Gama Participações Ltda.PJ1.52%0.00%1.52%
Elbrus Participações Ltda.PJ0.42%0.00%0.42%
Others (market)———35.95%
Treasury shares———0.00%

Direct holdings from the reference form (FRE) filed on 2026-09-16, version 5. The chain of control (who owns the holding) is not reproduced here. Names of individuals appear as in the public filing.

Filings and notices

filedcategorysubjectdocument
2026-09-14Calendário de Eventos Corporativos—open
2026-09-14Reunião da Administração · Conselho de Administração(i) Deliberar sobre a destituição do Sr. Luciano da Silva Machado do cargo de Diretor de Operações da Companhia ("Destituição Diretor de Operações")||(ii) Eleição do novo Diretor dopen
2026-09-10Valores Mobiliários negociados e detidos (art. 11 da Instr. CVM nº 358) · Posição Consolidada—open
2026-09-04Assembleia · AGEAlterar e consolidar o Estatuto Social da Companhia a fim de refletir o aumento do limite do capital autorizado||Aumentar o limite do capital autorizado da Companhia||Autorizar a aopen
2026-09-04Assembleia · AGE—open
2026-09-04Assembleia · AGEAlterar e consolidar o Estatuto Social da Companhia a fim de refletir o aumento do limite do capital autorizado||Aumentar o limite do capital autorizado da Companhia||Autorizar a aopen
2026-09-04Assembleia · AGEAlterar e consolidar o Estatuto Social da Companhia a fim de refletir o aumento do limite do capital autorizado||Aumentar o limite do capital autorizado da Companhia||Autorizar a aopen
2026-09-02Comunicado ao Mercado · Outros Comunicados Não Considerados Fatos RelevantesPrévias Operacionaisopen
2026-08-31Fato RelevanteEmissão privada de Debêntures Simplesopen
2026-08-31Reunião da Administração · Conselho de AdministraçãoContratação de empréstimo-ponte junto ao Banco XPopen

The last filings this company sent to the CVM outside its financial statements, newest first, from the regulator's own IPE index. The subject line is the company's own free text. We do not summarise or classify these documents — read the original.

Piotroski F-Score 4/9 (2025) — what each criterion means.

Restated filings for this company

The regulator overwrites the old version; we keep both. Figures in R$ millions: first filing on the left, restatement on the right.

fiscal yearaccountfirst filingrestated
2018BPA 1.01.0115.821.0
2014DFC_MI 6.01-19.8-16.5
2019DFC_MI 6.01-80.9-77.6
2018DFC_MI 6.01-44.1-45.9
2020DFC_MI 6.01-96.9-95.2
2012BPA 18.37.0
2012BPP 28.37.0
2010DMPL 5.05.01-4.0-4.3

Every restatement of this company, year by year

This company appears in

Compare

Side by side, with each figure's caveat and how often each company restated its filings.

BIOM3 × RDOR3 · BIOM3 × DASA3 · BIOM3 × HAPV3 · BIOM3 × HYPE3 · BIOM3 × NATU3 · BIOM3 × FLRY3

compare with the sector: HYPE3 × NATU3 × BLAU3

Other companies in Healthcare

15 more with a page, same CVM sector — a classification of the regulator's, not ours.

Take this into your code

Everything on this page is also JSON: GET /empresas/BIOM3/indicadores. WEGE3 is open for testing without a key; for the rest, create a free key (200 calls/day, no card).

Price coverage: 2,857 sessions, 2010-04-23 → 2026-09-25 · methodology · how we verify

Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.

Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-28 05:38 UTC. If this does not match /saude, you are reading a cached copy.